- Home
- DNA
as 02-04-2025 2:32pm EST
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 562.1M | IPO Year: | N/A |
| Target Price: | $37.80 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.26 - $64.40 | Next Earning Date: | 02-27-2025 |
| Revenue: | $217,951,000 | Revenue Growth: | -30.81% |
| Revenue Growth (this year): | -8.52% | Revenue Growth (next year): | -10.51% |
Latest Ginkgo Bioworks Holdings Inc. News
DNA Breaking Stock News: Dive into DNA Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know
PR Newswire
13 days ago
Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)
PR Newswire
23 days ago
Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors
PR Newswire
a month ago
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Zacks
2 months ago
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy
PR Newswire
2 months ago
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
Simply Wall St.
3 months ago
Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations
PR Newswire
3 months ago
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
Compare DNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNA Ginkgo Bioworks Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.